|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Follow-up of intestinal metaplasia in the stomach: When, how and why显示文摘Gastric cancer remains the second most frequent cause of cancer-related mortality in the world. Screening programs in some Asian countries are impractical in the majority of other countries worldwide. Therefore, follow-up of precancerous lesions is advisable for secondary gastric cancer prevention. Intestinal metaplasia (IM) is recognized as a precancerous lesion for gastric cancer, increasing the risk by 6-fold. IM is highly prevalent in the general population, being detected in nearly 1 of every 4 patients undergoing upper endoscopy. The IM prevalence rate is significantly higher in patients with Helicobacter pylori (H. pylori) infection, in first-degree relatives of gastric cancer patients, in smokers and it increases with patient age. IM is the 'breaking point' in the gastric carcinogenesis cascade and does not appear to regress following H. pylori eradication, although the cure of infection may slow its progression. Gastric cancer risk is higher in patients with incomplete-type IM, in those with both antral and gastric body involvement, and the risk significantly increases with IM extension over 20% of the gastric mucosa. Scheduled endoscopic control could be cost-effective in IM patients, depending on the yearly incidence of gastric cancer in IM patients, the stage of gastric cancer at diagnosis discovered at surveillance, and the cost of endoscopy. As a pragmatic behavior, yearly endoscopic control would appear justified in all IM patients with at least one of these conditions: (1) IM extension > 20%; (2) the presence of incomplete type IM; (3) first-degree relative of gastric cancer patients; and (4) smokers. In the remaining IM patients, a less intensive (2-3 years) could be proposed. | Angelo Zullo Cesare Hassan Adriana Romiti Michela Giusto Carmine Guerriero Roberto Lorenzetti Salvatore MA Campo Silverio Tomao | 2012 | World Journal of Gastrointestinal Oncology2012，4，3： | 25 |
| 2 | Rifaximin therapy and hepatic encephalopathy:Pros and cons显示文摘Hepatic encephalopathy(HE) is the second most common major complication in cirrhotics and it significantly impacts quality of life.Therapeutic approaches for HE treatment and prevention mainly continue to rely on ammonia-lowering strategies and non-absorbable disaccharides are currently considered the cornerstone therapy.Non-absorbable antibiotics,such as neomycin and paramomycin,are effective in treatment of acute HE episodes but their prolonged use for recurrence prevention is hampered by possible side-effects.To overcome these limitations,rifaximin use has been proposed.Rifaximin has been shown to be not superior to non-absorbable disaccharides for either HE treatment or prevention,with a similar incidence of side-effects.Cirrhosis significantly increases rifaximin absorption and this could be a cause for concern.Following long-term rifaximin therapy,Clostridium difficile colitis has been observed and Candida albicans has been isolated from 20% of patients.In addition,selection of resistant mutants of both Gram-negative and-positive bacteria in the gastrointestinal tract cannot be definitely ruled out.Electrolyte alterations(sodium and potassium) have been reported during rifaximin therapy,a warning for its long-term use in cirrhotics.Moreover,a potential interference with vitamin K production should be considered which could further impair the already altered clotting status of these patients.The therapeutic cost of rifaximin is markedly higher than non-absorbable disaccharides.While waiting for further safety data,caution should be used to limit the use of rifaximin therapy for a very short-term period in selected HE cirrhotics not responding to nonabsorbable disaccharides. | Angelo Zullo Cesare Hassan Lorenzo Ridola Roberto Lorenzetti Salvatore MA Campo Oliviero Riggio | 2012 | World Journal of Gastrointestinal Pharmacology and Therapeutics2012，3，4： | 2 |
| 3 | Update on urodynamic bladder dysfunctions after radical hysterectomy for cervical cancer显示文摘 | Plotti F Angioli R Zullo MA | | 0，，： | 1 |
| 4 | Bleeding Peptic Ulcer in the Elderly: Risk Factors and Prevention Strategies 显示文摘 | Zullo Angelo Hassan Cesare Campo Salvatore MA | 2007 | Drags &Aging2007，24，10： | 1 |
| 5 | Vesical dysfunctions after radical hysterectomy for cervical cancer:a critical review显示文摘 | Zullo MA Manci N Angioli R | | 0，，03： | 1 |
| 6 | Long-term bladder function in patients with locally advanced cervical carcinoma treated with neoadjuvant chemotherapy and type 3-4 radical hysterectomy显示文摘 | Benedetti-Panici P Zullo MA Plotti F | 2004 | Cancer2004，100，10： | 1 |
| 7 | Long-term bladder function in patients with locally advanced cervical carcinoma treated with neoadjuvant chemotherapy and type 3-4 radical hysterectomy显示文摘 | Benedetti-Panici P Zullo MA Plotti F | 2004 | Cancer2004，100，10： | 1 |
| 8 | Long-term bladder function in patients with locally advanced cervical carcinoma treated with neoadjuvant chemotherapy and type 3-4 radical hysterectomy 显示文摘 | Benedetti-Panici P Zullo MA Plotti F | 2004 | Cancer2004，100，10： | 1 |
| 9 | Vaginal estrogen therapy and overactive bladder symptoms in postmenopausal patients after a tension-free vaginal tape procedure:a randomized clinical trial显示文摘 | Plotti F Calcagno M | 2005 | Menopause2005，12，： | 1 |
| 10 | Vesical dysfunctions after radical hysterectomy for cervical cancer: a critical review 显示文摘 | Zullo MA Manci N Angioli R | 2003 | Crit Rev Oncol Hematol2003，48，3： | 1 |
| 11 | Long-term bladder function in patients with locally advanced cervical carcinoma treated with neoadjuvant chemotherapy and type 3-4 radical hysterectomy 显示文摘 | Benedetti PP Zullo MA Plotti F | 2004 | Cancer2004，100，10： | 1 |
| 12 | Diagnostic open laparoscopy in the management of advanced ovarian cancer显示文摘 | Angioli R Palaia I Zullo MA | 2006 | Gynecol Oncol2006，100，3： | 1 |
| 13 | Longterm bladder unction in patients with locally advanced cervical carcinoma treated with neoadju- vant chemotherapy and type 3-4 radical hysterectomy显示文摘 | Benedetti-Panici P Zullo MA Plotti F | 2004 | Cancer2004，100，10： | 1 |
| 14 | One-year follow-up of tension-free vaginal tape(TVT) and trans-obturator suburethral tape from inside to outside(TVT-O) for surgical treatment of female stress urinary incontinence:a prospective randomised trial显示文摘 | Zullo MA Plotti F Calcagno M | 2007 | Eur Urol2007，51，5： | 1 |
| 15 | Long-term bladder function in patients with locally advanced cervical carcinoma treated with neoadjuvant chemotherapy and type 34 radical hysterectomy 显示文摘 | Benedetti-Panici P Zullo MA Plotti F | 2004 | Cancer2004，100，： | 1 |
| 16 | Vesical dysfunctions after radical hysterectomy for cervical cancer: a critical review显示文摘 | Zullo MA Manci N Angioli R | 2003 | Crit Rev Oncol Hematol2003，48，3： | 1 |
| 17 | Vesieal dysfunctions after radical hysterectomy for cervical cancer:a critical review 显示文摘 | Zullo MA Manci N Angioli R | 2003 | Crit Rev Oncol Hematol2003，48，3： | 1 |
| 18 | Vesical dysfunctions after radical hysterectomy for cervical cancer: a critical review 显示文摘 | Zullo MA Manci N Angioli R | 2003 | Crit Rev Oncol Hematol2003，48，3： | 1 |
| 19 | Post radical hysterectomy urinary incontinence:A prospective study of transurethral bulking agents injection显示文摘 | Plotti F Zullo MA Sansone M et a1 | 2009 | Gyneeol Oncol2009，112，1： | 1 |
| 20 | Update on urodynam- ic bladder dysfunctions after radical hysterectomy for cer- vical cancer显示文摘 | Plotti F Angioli R Zullo MA | 2011 | Crit Rev Oncol Hematol2011，80，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员